FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367312345> ?p ?o ?g. }

• W4367312345 endingPage "107327482311734" @default.
• W4367312345 startingPage "107327482311734" @default.
• W4367312345 abstract "People living with HIV (PLWH) have a worse prognosis than the general population. Locally advanced or metastatic bladder cancer (BCa) in PLWH has gradually been increasing in recent years. Immune checkpoint inhibitors can improve antitumor activity in the general population, but relevant data in PLWH are unknown. We thus evaluated the efficacy and safety of tislelizumab in PLWH with locally advanced or metastatic BCa.This retrospective study included 24 patients with locally advanced or metastatic BCa, both HIV positive or negative who underwent tislelizumab treatment (200 mg i.v. every 3 weeks, Q3W) from the multi-centers between December 2019 and March 2022. Demographic details, clinical data, and cancer status were collected. The overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), and treatment-related adverse events (TRAEs) were recorded and evaluated.A total of 24 individuals were chosen for this study, 10 had HIV and the other 14 did not. The median OS in the HIV-negative group was 62.3 (95% CI, 52.6 to 72.2) was no longer than that of the PLWH group 41.9 (95% CI, 32.9 to 51.0) weeks (HR .7, [95% CI, .17 to 3.30], P = .70). Furthermore, the median PFS in the HIV-negative group was 50.0 (95% CI, 36.2 to 63.9) was also no longer than that of the PLWH group 35.9 (95% CI, 25.5 to 46.3) (HR, 1.34, [95% CI, .38 to 4.69], P = .63). Of 24 patients, treatment-related adverse events, grade 3 or 4 occurred in 2 in the PLWH group and 3 in the HIV-negative group.This retrospective multi-center study suggested that tislelizumab may provide encouraging antitumor activity and could be generally well tolerated. In this retrospective analysis of patients with locally advanced or metastatic BCa, it seems that PLWH may have similar overall and progression-free survival compared to HIV-negative cases." @default.
• W4367312345 created "2023-04-29" @default.
• W4367312345 creator A5034630104 @default.
• W4367312345 creator A5043256138 @default.
• W4367312345 creator A5056909108 @default.
• W4367312345 creator A5070573479 @default.
• W4367312345 creator A5071773009 @default.
• W4367312345 creator A5077734404 @default.
• W4367312345 date "2023-04-28" @default.
• W4367312345 modified "2023-09-30" @default.
• W4367312345 title "The Efficacy and Safety of Tislelizumab as Adjuvant Treatment for Advanced or Metastatic Bladder Cancer in People Living With HIV: A Retrospective Multi-Center Study" @default.
• W4367312345 cites W2059796825 @default.
• W4367312345 cites W2103257412 @default.
• W4367312345 cites W2148562299 @default.
• W4367312345 cites W2151488185 @default.
• W4367312345 cites W2462649057 @default.
• W4367312345 cites W2559804019 @default.
• W4367312345 cites W2573606639 @default.
• W4367312345 cites W2582671354 @default.
• W4367312345 cites W2588916311 @default.
• W4367312345 cites W2760661635 @default.
• W4367312345 cites W2789343266 @default.
• W4367312345 cites W2799565954 @default.
• W4367312345 cites W2883778230 @default.
• W4367312345 cites W2943108118 @default.
• W4367312345 cites W2943800885 @default.
• W4367312345 cites W2946998144 @default.
• W4367312345 cites W2955805012 @default.
• W4367312345 cites W2983476233 @default.
• W4367312345 cites W2987564581 @default.
• W4367312345 cites W3012466751 @default.
• W4367312345 cites W3024551702 @default.
• W4367312345 cites W3086850485 @default.
• W4367312345 cites W3092442011 @default.
• W4367312345 cites W3094891754 @default.
• W4367312345 cites W3102493364 @default.
• W4367312345 cites W3136847146 @default.
• W4367312345 cites W3159956841 @default.
• W4367312345 cites W3161379202 @default.
• W4367312345 cites W3163995648 @default.
• W4367312345 cites W3164197656 @default.
• W4367312345 cites W3206593389 @default.
• W4367312345 cites W3209393335 @default.
• W4367312345 cites W4280534053 @default.
• W4367312345 cites W4281781908 @default.
• W4367312345 cites W4284968454 @default.
• W4367312345 cites W4292471386 @default.
• W4367312345 cites W4292688946 @default.
• W4367312345 cites W4306797808 @default.
• W4367312345 doi "https://doi.org/10.1177/10732748231173475" @default.
• W4367312345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37115019" @default.
• W4367312345 hasPublicationYear "2023" @default.
• W4367312345 type Work @default.
• W4367312345 citedByCount "0" @default.
• W4367312345 crossrefType "journal-article" @default.
• W4367312345 hasAuthorship W4367312345A5034630104 @default.
• W4367312345 hasAuthorship W4367312345A5043256138 @default.
• W4367312345 hasAuthorship W4367312345A5056909108 @default.
• W4367312345 hasAuthorship W4367312345A5070573479 @default.
• W4367312345 hasAuthorship W4367312345A5071773009 @default.
• W4367312345 hasAuthorship W4367312345A5077734404 @default.
• W4367312345 hasBestOaLocation W43673123451 @default.
• W4367312345 hasConcept C121608353 @default.
• W4367312345 hasConcept C126322002 @default.
• W4367312345 hasConcept C143998085 @default.
• W4367312345 hasConcept C167135981 @default.
• W4367312345 hasConcept C197934379 @default.
• W4367312345 hasConcept C203014093 @default.
• W4367312345 hasConcept C2777863537 @default.
• W4367312345 hasConcept C2780352672 @default.
• W4367312345 hasConcept C2908647359 @default.
• W4367312345 hasConcept C3013748606 @default.
• W4367312345 hasConcept C71924100 @default.
• W4367312345 hasConcept C99454951 @default.
• W4367312345 hasConceptScore W4367312345C121608353 @default.
• W4367312345 hasConceptScore W4367312345C126322002 @default.
• W4367312345 hasConceptScore W4367312345C143998085 @default.
• W4367312345 hasConceptScore W4367312345C167135981 @default.
• W4367312345 hasConceptScore W4367312345C197934379 @default.
• W4367312345 hasConceptScore W4367312345C203014093 @default.
• W4367312345 hasConceptScore W4367312345C2777863537 @default.
• W4367312345 hasConceptScore W4367312345C2780352672 @default.
• W4367312345 hasConceptScore W4367312345C2908647359 @default.
• W4367312345 hasConceptScore W4367312345C3013748606 @default.
• W4367312345 hasConceptScore W4367312345C71924100 @default.
• W4367312345 hasConceptScore W4367312345C99454951 @default.
• W4367312345 hasLocation W43673123451 @default.
• W4367312345 hasLocation W43673123452 @default.
• W4367312345 hasLocation W43673123453 @default.
• W4367312345 hasOpenAccess W4367312345 @default.
• W4367312345 hasPrimaryLocation W43673123451 @default.
• W4367312345 hasRelatedWork W1973460911 @default.
• W4367312345 hasRelatedWork W1979321249 @default.
• W4367312345 hasRelatedWork W2096903645 @default.
• W4367312345 hasRelatedWork W2349999257 @default.
• W4367312345 hasRelatedWork W2415761310 @default.
• W4367312345 hasRelatedWork W2474195589 @default.
• W4367312345 hasRelatedWork W3013145321 @default.

• next